Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GBA1 | P04062 | 1/20 | 0.41 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TACR1 | P25103 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22570100 | 0.88 | TACR1 (0.46) | SLC18A3SIGMAR1TSHRTACR1 | |
| SCHEMBL22570096 | 0.88 | TACR1 (0.46) | SLC18A3SIGMAR1TSHRTACR1 | |
| SCHEMBL21163277 | 0.88 | TACR1 (0.46) | SLC18A3SIGMAR1TSHRTACR1 | |
| SCHEMBL15922404 | 0.88 | TACR1 (0.46) | SLC18A3SIGMAR1TSHRTACR1 | |
| SCHEMBL14504584 | 0.88 | TACR1 (0.46) | SLC18A3SIGMAR1TSHRTACR1 | |
| SCHEMBL25360423 | 0.88 | TACR1 (0.46) | SLC18A3SIGMAR1TSHRTACR1 | |
| SCHEMBL166543 | 0.80 | PRCP (0.38) | TACR1 | |
| SCHEMBL20364476 | 0.78 | GBA1 (0.53) | SLC18A3SIGMAR1SLC6A2ADRA1AHTR2B | |
| SCHEMBL430840 | 0.78 | P2RX7 (0.40) | SLC6A2HTR2BSLC6A3 | |
| SCHEMBL8222209 | 0.77 | SLC18A3 (0.52) | SLC18A3SIGMAR1SLC6A2ADRA1AHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024081363-A1 | COMPOSITION COMPRISING A FIRST RAS INHIBITOR, SECOND RAS INHIBITOR AND A SHP2 INHIBITOR FOR USE IN THE TREATMENT OF CANCER | Revolution Medicines, Inc. (US) | 2024-04-18 | — | — | WO | disclosed |
| US-7622585-B2 | Phenylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-11-24 | — | — | US | disclosed |